Results 11 to 20 of about 2,864 (172)
Profile of delamanid for the treatment of multidrug-resistant tuberculosis
Drug Design, Development and Therapy, 2015 John D Szumowski,1,2 John B Lynch11Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA; 2Division of AIDS Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA Abstract: New approaches
Szumowski JD, Lynch JB
doaj +5 more sources
Delamanid or pretomanid? A Solomonic judgement! [PDF]
Journal of Antimicrobial Chemotherapy, 2022 Abstract Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are urgently needed. The landscape of TB treatment has changed considerably over the last decade with the approval of three new compounds: bedaquiline, delamanid and pretomanid. Of these, delamanid and pretomanid belong to the same class of
Saskia E. Mudde +4 more
openaire +2 more sources
International Journal of Mycobacteriology, 2023 Background: Drug-resistant tuberculosis (DR-TB) is a public health concern that is difficult to treat, requiring long and complex treatment with highly effective drugs.
Oki Nugraha Putra +3 more
doaj +1 more source
EClinicalMedicine, 2020 Background: Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10–19 years) with injectable-free regimens containing these drugs in ...
Erika Mohr-Holland +9 more
doaj +1 more source
Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
Lung India, 2023 Tuberculosis is a leading cause of death in our country. Multidrug-resistant tuberculosis increases the morbidity and mortality due to severe manifestations and difficult and prolonged medications.
Vikas Marwah +3 more
doaj +1 more source
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
eLife, 2016 There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania ...
Stephen Patterson +8 more
doaj +1 more source
Туберкулез и болезни лёгких, 2021 The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.
A. E. Russkikh +4 more
doaj +1 more source
Туберкулез и болезни лёгких, 2023 The objective: to evaluate the toxicity of combinations of delamanid and drugs for treatment of drug resistant tuberculosis with different safety profiles in an experiment.Results.
G. N. Mozhokina +3 more
doaj +1 more source
Emerging Infectious Diseases, 2023 New classes of antitubercular drugs, diarylquinolines and nitroimidazoles, have been associated with improved outcomes in the treatment of drug-resistant tuberculosis, but that success is threatened by emerging drug resistance.
James Millard +3 more
doaj +1 more source
The Prospective Synergy of Antitubercular Drugs With NAD Biosynthesis Inhibitors
Frontiers in Microbiology, 2021 Given the upsurge of drug-resistant tuberculosis worldwide, there is much focus on developing novel drug combinations allowing shorter treatment duration and a lower toxicity profile.
Kyle H. Rohde, Leonardo Sorci
doaj +1 more source